11:34:05 EDT Sun 23 Jun 2024
Enter Symbol
or Name
USA
CA



Cybin Inc
Symbol CYBN
Shares Issued 405,910,711
Close 2023-12-05 C$ 0.57
Market Cap C$ 231,369,105
Recent Sedar Documents

Cybin receives U.S. patent for CYB003 program

2023-12-06 10:41 ET - News Release

Mr. Doug Drysdale reports

CYBIN ANNOUNCES GRANT OF ADDITIONAL U.S. PATENT IN SUPPORT OF ITS CYB003 DEUTERATED PSILOCYBIN ANALOG PROGRAM

The United States Patent and Trademark Office (USPTO) has granted Cybin Inc. U.S. patent 11,834,410 in support of its CYB003 program.

The patent, which is expected to provide exclusivity until at least 2041, includes composition of matter claims to pharmaceutical compositions within the company's proprietary deuterated psilocybin analogue program, CYB003, as well as claims directed toward the therapeutic treatment of major depressive disorder (MDD), treatment-resistant depression and alcohol use disorder.

"Securing robust patent protection for our proprietary products is a top priority, and we are pleased to announce this additional U.S. patent supporting our CYB003 program," said Doug Drysdale, chief executive officer of Cybin. "Last week, we shared positive phase 2 top-line safety and efficacy data for CYB003 in MDD. In addition to the rapid, robust and statistically significant reduction in depression symptoms observed three weeks following a single 12-milligram dose of CYB003 compared to placebo, we also saw a sustained improvement at six weeks, as well as impressive response and remission rates of 79 per cent for patients who received two doses. We are extremely pleased with the data and the potential to deliver meaningfully improved treatment options for people with mental health disorders and are eager to progress our CYB003 program through the next regulatory steps."

About Cybin Inc.

Cybin is a clinical-stage biopharmaceutical company on a mission to create safe and effective psychedelic-based therapeutics to address the large unmet need for new and innovative treatment options for people who suffer from mental health conditions.

Cybin's goal of revolutionizing mental health care is supported by a network of world-class partners and internationally recognized scientists aimed at progressing proprietary drug discovery platforms, innovative drug delivery systems, and novel formulation approaches and treatment regimens. The company is currently developing CYB003, a proprietary deuterated psilocybin analogue for the treatment of major depressive disorder and CYB004, a proprietary deuterated DMT (N,N-dimethyltryptamine) molecule for generalized anxiety disorder and has a research pipeline of investigational psychedelic-based compounds.

Headquartered in Canada and founded in 2019, Cybin is operational in Canada, the United States, the United Kingdom, the Netherlands and Ireland.

We seek Safe Harbor.

© 2024 Canjex Publishing Ltd. All rights reserved.